Merkel Cell Carcinoma - Pipeline Review, H1 2017

  • ID: 4318737
  • Drug Pipelines
  • 257 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • BeiGene (Beijing) Co Ltd
  • Immune Design Corp
  • Merck KGaA
  • Novartis AG
  • Oncovir Inc
  • MORE
Merkel Cell Carcinoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2017, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 9, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • BeiGene (Beijing) Co Ltd
  • Immune Design Corp
  • Merck KGaA
  • Novartis AG
  • Oncovir Inc
  • MORE
  1. Introduction
  2. Merkel Cell Carcinoma - Overview
  3. Merkel Cell Carcinoma - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Merkel Cell Carcinoma - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Merkel Cell Carcinoma - Companies Involved in Therapeutics Development
  15. Amgen Inc
  16. Apcure SAS
  17. BeiGene (Beijing) Co Ltd
  18. Bristol-Myers Squibb Company
  19. F. Hoffmann-La Roche Ltd
  20. Immune Design Corp
  21. Merck & Co Inc
  22. Merck KGaA
  23. Millennium Pharmaceuticals Inc
  24. NantKwest Inc
  25. Novartis AG
  26. OncoSec Medical Inc
  27. Oncovir Inc
  28. Ono Pharmaceutical Co Ltd
  29. Philogen SpA
  30. Tarveda Therapeutics Inc
  31. Merkel Cell Carcinoma - Drug Profiles
  32. APC-001 - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. atezolizumab - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. avelumab - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. bevacizumab - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. BGBA-317 - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. Cellular Immunotherapy 1 for Oncology - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. Cellular Immunotherapy 2 for Oncology - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. G-100 - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. ipilimumab + nivolumab - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. MAL-3101 - Drug Profile
  69. Product Description
  70. Mechanism Of Action
  71. R&D Progress
  72. nivolumab - Drug Profile
  73. R&D Progress
  74. pasireotide - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. pasireotide ER - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. pazopanib hydrochloride - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. pembrolizumab - Drug Profile
  87. R&D Progress
  88. PEN-221 - Drug Profile
  89. Product Description
  90. Mechanism Of Action
  91. R&D Progress
  92. Poly-ICLC - Drug Profile
  93. Product Description
  94. Mechanism Of Action
  95. R&D Progress
  96. sapanisertib - Drug Profile
  97. Product Description
  98. Mechanism Of Action
  99. R&D Progress
  100. talimogene laherparepvec - Drug Profile
  101. Product Description
  102. Mechanism Of Action
  103. R&D Progress
  104. tavokinogene telseplasmid - Drug Profile
  105. Product Description
  106. Mechanism Of Action
  107. R&D Progress
  108. Teleukin - Drug Profile
  109. Product Description
  110. Mechanism Of Action
  111. R&D Progress
  112. tigilanol tiglate - Drug Profile
  113. Product Description
  114. Mechanism Of Action
  115. R&D Progress
  116. Vaccine to Target WT1 for Oncology - Drug Profile
  117. Product Description
  118. Mechanism Of Action
  119. R&D Progress
  120. Merkel Cell Carcinoma - Product Development Milestones
  121. Featured News & Press Releases
  122. May 31, 2017: Triple therapy for rare skin cancer shows promise in small, early-stage trial
  123. May 17, 2017: Merck and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO
  124. Mar 29, 2017: BAVENCIO (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics
  125. Mar 23, 2017: FDA Grants Approval for BAVENCIO (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
  126. Mar 20, 2017: NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
  127. Mar 01, 2017: Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR
  128. Nov 29, 2016: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
  129. Nov 14, 2016: NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
  130. Oct 31, 2016: European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
  131. Sep 28, 2016: Merck to Present Data on Avelumab at ESMO
  132. Appendix
  133. Methodology
  134. Coverage
  135. Secondary Research
  136. Primary Research
  137. Expert Panel Validation
  138. Contact Us
  139. Disclaimer
List of Tables
  1. Number of Products under Development for Merkel Cell Carcinoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Companies, H1 2017 (Contd..1), H1
  6. Products under Development by Universities/Institutes, H1
  7. Number of Products by Stage and Target, H1
  8. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  9. Number of Products by Stage and Mechanism of Action, H1
  10. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  11. Number of Products by Stage and Route of Administration, H1
  12. Number of Products by Stage and Molecule Type, H1
  13. Merkel Cell Carcinoma - Pipeline by Amgen Inc, H1
  14. Merkel Cell Carcinoma - Pipeline by Apcure SAS, H1
  15. Merkel Cell Carcinoma - Pipeline by BeiGene (Beijing) Co Ltd, H1
  16. Merkel Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1
  17. Merkel Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1
  18. Merkel Cell Carcinoma - Pipeline by Immune Design Corp, H1
  19. Merkel Cell Carcinoma - Pipeline by Merck & Co Inc, H1
  20. Merkel Cell Carcinoma - Pipeline by Merck KGaA, H1
  21. Merkel Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H1
  22. Merkel Cell Carcinoma - Pipeline by NantKwest Inc, H1
  23. Merkel Cell Carcinoma - Pipeline by Novartis AG, H1
  24. Merkel Cell Carcinoma - Pipeline by OncoSec Medical Inc, H1
  25. Merkel Cell Carcinoma - Pipeline by Oncovir Inc, H1
  26. Merkel Cell Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H1
  27. Merkel Cell Carcinoma - Pipeline by Philogen SpA, H1
  28. Merkel Cell Carcinoma - Pipeline by Tarveda Therapeutics Inc, H1
List of Figures
  1. Number of Products under Development for Merkel Cell Carcinoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Top 10 Molecule Types, H1
  11. Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Apcure SAS
  • BeiGene (Beijing) Co Ltd
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Immune Design Corp
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • NantKwest Inc
  • Novartis AG
  • OncoSec Medical Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Philogen SpA
  • Tarveda Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll